TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27633168

Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise program for 12 weeks
Number of subjects: 36
Study: 25033150

Group type: EXPERIMENTAL
Intervention: Shape Program (weight gain prevention intervention)
Number of subjects: 0
Study: 23510724

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius Ls-33
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22117984

Group type: EXPERIMENTAL
Intervention: TIVA (propofol‐remifentanil [target blood concentrations 2.5 ‐ 3.5 μg/ml and 3.5 ‐ 4.5 ng/ml])
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Combined inhalation and intravenous anaesthesia (sevoflurane 1.0 vol% in 50% air plus propofol‐remifentanil [target blood concentrations 1.5 ‐ 2.5 μg/ml and 2.5 ‐ 3.5 ng/ml])
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sevoflurane (thiopental sodium 4 ‐ 5 mg/kg and sevoflurane 2.0 ‐ 2.5 vol% in 50% air)
Number of subjects: 177
Study: 19271172

Group type: EXPERIMENTAL
Intervention: Lamivudine combined with SPNS formula
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lamivudine only
Number of subjects: 60
Study: 16490647

Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (10 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study: 14714106

Group type: EXPERIMENTAL
Intervention: Waiver of consent from the patient's next of kin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard consent process (before waiver)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Informed consent obtained from patients or next of kin
Number of subjects: 300
Study: 10940797

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 400 mug twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9028547

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8365089

Group type: EXPERIMENTAL
Intervention: B28Asp (0.15 U kg‐1 body weight)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Soluble human insulin (0.15 U kg‐1 body weight)
Number of subjects: 14
Study: 6149992

Group type: EXPERIMENTAL
Intervention: Cimetidine (1,000 mg per day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg per day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine (120 mg per kg body weight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine (120 mg per kg body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 8
Study: 30677084

Group type: EXPERIMENTAL
Intervention: Self-persuasion anti-alcohol poster (framed as a question)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Direct persuasion anti-alcohol poster (framed as a statement)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control condition (no poster)
Number of subjects: 149
Study: 29372578

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided approach
Number of subjects: 129

Group type: COMPARATOR
Intervention: Anatomical landmark approach
Number of subjects: 129
Study: 27444428

Group type: EXPERIMENTAL
Intervention: Intensive Treatment (IT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 0
Study: 24470257

Group type: EXPERIMENTAL
Intervention: Pressing to start and stop the interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous pressing during the interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Just pressing at the end of the interval
Number of subjects: 0
Study: 22108529

Group type: EXPERIMENTAL
Intervention: Self-paced continuous steady rate swim of 20 minutes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Coach-administered modified warm-up consisting of various swimming modes, intensities, and rest intervals for 20 minutes
Number of subjects: 33

Group type: COMPARATOR
Intervention: Land-based recovery consisting of light-intensity walking, skipping, and stretching for 20 minutes
Number of subjects: 33
Study: 20698844

Group type: EXPERIMENTAL
Intervention: 0.1% DHEA cream
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.3% DHEA cream
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1% DHEA cream
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2% DHEA cream
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 16940735

Group type: EXPERIMENTAL
Intervention: Functional tasks exercise programme (function group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Resistance exercise programme (resistance group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Normal activity group (control group)
Number of subjects: 98
Study: 16750466

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5%
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 29
Study: 15573827

Group type: EXPERIMENTAL
Intervention: Education group (EG)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (CoG)
Number of subjects: 114
Study: 11236238

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 18
Study: 8641599

Group type: EXPERIMENTAL
Intervention: Subcutaneous fluids (s.c.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous fluids (i.v.)
Number of subjects: 60
Study: 1634173

Group type: EXPERIMENTAL
Intervention: Topical combination preparation containing standardized leech extract, polidocanol and allantoin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 6095468

Group type: EXPERIMENTAL
Intervention: Prednisolone 3 mg/kg/d for 1 week
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin 100 mg/kg on 2 successive days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1000 mg 3 times a day for 1 week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study: 31810797

Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg orally once daily in 4-week cycles
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily continuously
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 350
Study: 30006860

Group type: EXPERIMENTAL
Intervention: n-back training (experimental condition)
Number of subjects: 52

Group type: COMPARATOR
Intervention: no-contact control condition
Number of subjects: 52
Study: 28678953

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide followed by the application of CPP-ACPF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide followed by the application of NovaMin
Number of subjects: 60

Group type: COMPARATOR
Intervention: 35% hydrogen peroxide
Number of subjects: 60
Study: 25944156

Group type: EXPERIMENTAL
Intervention: 1 g topical TXA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2 g intravenous TXA
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine hemostasis (control group)
Number of subjects: 150
Study: 24074484

Group type: EXPERIMENTAL
Intervention: Fixed dose aripiprazole (3mg/day)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Flexible dose aripiprazole (3-15 mg/day)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 22110105

Group type: EXPERIMENTAL
Intervention: Sodium excretion > 7 g/day
Number of subjects: 28880

Group type: EXPERIMENTAL
Intervention: Sodium excretion < 3 g/day
Number of subjects: 28880

Group type: EXPERIMENTAL
Intervention: Potassium excretion 1.5-1.99 g/day
Number of subjects: 28880

Group type: EXPERIMENTAL
Intervention: Potassium excretion 2-2.49 g/day
Number of subjects: 28880

Group type: EXPERIMENTAL
Intervention: Potassium excretion 2.5-3 g/day
Number of subjects: 28880

Group type: EXPERIMENTAL
Intervention: Potassium excretion > 3 g/day
Number of subjects: 28880

Group type: COMPARATOR
Intervention: Sodium excretion 4-5.99 g/day
Number of subjects: 28880
Study: 19619703

Group type: EXPERIMENTAL
Intervention: ADRB2 rs180088
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: PAI1 rs1799768
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: C5 rs17611
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: CTLA4 rs5742909
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: ADRB2 rs180088 (postmenopausal women)
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: PAI1 rs1799768 (postmenopausal women)
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: SCNN1A rs5742912 (postmenopausal women)
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: IL1A rs1800587 (postmenopausal women)
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: AGTR1 rs5186 (postmenopausal women)
Number of subjects: 20806

Group type: EXPERIMENTAL
Intervention: SCNN1A rs5742912 (current users of hormone therapy)
Number of subjects: 20806
Study: 17192690

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no topical agent)
Number of subjects: 60
Study: 14559694

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (30 degrees Celsius)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate hypothermia (26 degrees Celsius)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups during CPB
Number of subjects: 20
Study: 11021121

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (Dk = 140) worn for up to 30 days and nights
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etafilcon A (Dk = 28) worn for up to 7 days and 6 nights
Number of subjects: 0
Study: 8612379

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg orally three times a day for 2 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1315664

Group type: EXPERIMENTAL
Intervention: Intervention communities
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 11
Study: 6426754

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency coagulation of the Gasserian ganglion under neuroleptanalgesia and intermittent ultrashort‐acting barbiturate anaesthesia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency coagulation of the Gasserian ganglion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin during current generation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Percutaneous thermocoagulation of the Gasserian ganglion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Monitoring and protection during procedure
Number of subjects: 12
Study: 31801477

Group type: EXPERIMENTAL
Intervention: Childbirth Experience Questionnaire 2.0 (Farsi version)
Number of subjects: 500
Study: 29122195

Group type: EXPERIMENTAL
Intervention: Fit condition (balanced demand-skill level)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional N-Back task (high mental workload)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-demand level (boredom)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-demand level (anxiety)
Number of subjects: 0
Study: 26584404

Group type: EXPERIMENTAL
Intervention: 4g day(‐1) paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24197757

Group type: EXPERIMENTAL
Intervention: BCS+WBI (arm 1: 373 patients)
Number of subjects: 749

Group type: COMPARATOR
Intervention: BCS alone (arm 2: 376 patients)
Number of subjects: 749
Study: 22101392

Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring Systems (MEMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEMS
Number of subjects: 0
Study: 20955571

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage and drainage (LOLA-arm)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Hartmann's procedure or sigmoidectomy with primary anastomosis (LOLA-arm)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Hartmann's procedure (DIVA-arm)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Resection with primary anastomosis (DIVA-arm)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Both arms (secondary endpoints)
Number of subjects: 344
Study: 17685727

Group type: COMPARATOR
Intervention: Athletic Shoe (AS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Meridian Elyte (MS)
Number of subjects: 14
Study: 16362843

Group type: EXPERIMENTAL
Intervention: Sertraline with late partial sleep deprivation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sertraline with bright light therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sertraline monotherapy
Number of subjects: 37
Study: 11828949

Group type: EXPERIMENTAL
Intervention: 100 IU/kg of r‐huEPO
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 200 IU/kg of r‐huEPO
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: r‐huEPO (both doses)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: r‐huEPO
Number of subjects: 72
Study: 9564184

Group type: EXPERIMENTAL
Intervention: Almitrine 100 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Almitrine 75 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 7846198

Group type: EXPERIMENTAL
Intervention: Ipsapirone 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3053609

Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 29497863

Group type: EXPERIMENTAL
Intervention: Uric acid lowering treatment (specific intervention not detailed)
Number of subjects: 0
Study: 27919404

Group type: EXPERIMENTAL
Intervention: MCT+
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 92
Study: 26378067

Group type: EXPERIMENTAL
Intervention: 0.08 mg/kg oxycodone (Group O)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 1 µg/kg fentanyl (Group F)
Number of subjects: 54
Study: 23296279

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate for 24 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Other antihypertensive drugs (non-nitrate group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 64
Study: 21484744

Group type: EXPERIMENTAL
Intervention: Zirconia ceramic head, polyethylene cup (Group A)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cobalt‐Chrome‐Molybdenum head and cup (Group B)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Zirconia ceramic head, polyethylene moulded on the Titanium shell of the Asian cup (Group C)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Alumina head and cup (Group D)
Number of subjects: 205
Study: 18293149

Group type: EXPERIMENTAL
Intervention: CHO before 12:00 h (n=9)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CHO after 18:00 h (n=6)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PROT after 18:00 h (n=7)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 22
Study: 16812927

Group type: EXPERIMENTAL
Intervention: Multicomponent, family-based programs for children aged 5-12 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent, school-based programs for adolescents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community-based interventions
Number of subjects: 0
Study: 14633813

Group type: EXPERIMENTAL
Intervention: Triple therapy (insulin aspart, metformin, rosiglitazone)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (NPH or MIX insulin)
Number of subjects: 16
Study: 11077130

Group type: EXPERIMENTAL
Intervention: Sustained-release moxonidine 0.9 mg bid
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9401362

Group type: EXPERIMENTAL
Intervention: Near fatal asthma patients (n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 34
Study: 8354296

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate suspension given b.i.d. for seven days
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate suspension given t.i.d. for seven days
Number of subjects: 311

Group type: COMPARATOR
Intervention: Both treatment groups (b.i.d. and t.i.d.)
Number of subjects: 311
Study: 2885572

Group type: EXPERIMENTAL
Intervention: Intermediate-density lipoproteins (IDL)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cholestyramine treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ratios of HDL-cholesterol to total-cholesterol or LDL-cholesterol
Number of subjects: 57
Study: 30887126

Group type: EXPERIMENTAL
Intervention: Spiritual well-being
Number of subjects: 190

Group type: COMPARATOR
Intervention: Secure attachment
Number of subjects: 190
Study: 28241025

Group type: EXPERIMENTAL
Intervention: Internet-based CBT with therapist support (LITG)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Internet-based CBT without therapist support (TSG)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 296
Study: 26492167

Group type: EXPERIMENTAL
Intervention: Ablation treatment (coagulation) in Group A (small endometriomas)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Excision treatment in Group A (small endometriomas)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Excision treatment in Group B (large endometriomas)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ablation treatment (coagulation) in Group B (large endometriomas)
Number of subjects: 48
Study: 24008921

Group type: EXPERIMENTAL
Intervention: Moderate hyperventilation (partial pressure of carbon dioxide at 30 mmHg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moderate hypoventilation (partial pressure of carbon dioxide at 50 mmHg)
Number of subjects: 30
Study: 21157390

Group type: EXPERIMENTAL
Intervention: Weight Loss Supplement (WLS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study: 19412140

Group type: EXPERIMENTAL
Intervention: Workplace intervention
Number of subjects: 196
Study: 18097108

Group type: EXPERIMENTAL
Intervention: Intranasal 17 beta‐estradiol (300 microg/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol (50 microg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (Vaginal progesterone gel twice weekly)
Number of subjects: 80
Study: 15066049

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12488664

Group type: EXPERIMENTAL
Intervention: Short course ciprofloxacin (15 mg/kg every 12 h for 3 days followed by placebo for 2 days)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Standard course ciprofloxacin (15 mg/kg every 12 h for 5 days)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Both groups (short and standard course ciprofloxacin)
Number of subjects: 253
Study: 9400449

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 10 micrograms alprostadil plus genital plus audiovisual sexual stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Re-dosing of 10 micrograms alprostadil
Number of subjects: 20
Study: 7654128

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 50 mg/d
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 100 mg (single dose)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 150 mg/d
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 2667598

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of CGP 38 560 A at doses of 50, 125, and 250 micrograms kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of CGP 38 560 A at doses of 50, 100, and 200 mg
Number of subjects: 0
Study: 933252

Group type: EXPERIMENTAL
Intervention: Marihuana
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7001331

Group type: EXPERIMENTAL
Intervention: Vidarabine therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 31629831

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg, acute administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31752847

Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation Bronchoscopy (ENB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional bronchoscopy on phantom
Number of subjects: 48
Study: 28389705

Group type: EXPERIMENTAL
Intervention: Insulin infusion (3.0/1.5 mU kg‐1 min‐1) under hyperglycaemic ketotic conditions (KET)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Insulin infusion (3.0/1.5 mU kg‐1 min‐1) under euglycaemic conditions (CTR)
Number of subjects: 9
Study: 25884922

Group type: EXPERIMENTAL
Intervention: 8 week CBT group guided self-help intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care (Delayed Access Control)
Number of subjects: 46
Study: 23122669

Group type: EXPERIMENTAL
Intervention: DEX 0.5 μg/kg (group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo bolus (group C)
Number of subjects: 60
Study: 21183500

Group type: EXPERIMENTAL
Intervention: Cardiac troponin I (cTnI) ≥0.03 ng/mL
Number of subjects: 4352

Group type: EXPERIMENTAL
Intervention: N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥400 pg/mL
Number of subjects: 4352

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) ≥15 mg/L
Number of subjects: 4352

Group type: EXPERIMENTAL
Intervention: Myeloperoxidase (MPO) ≥670 pmol/L
Number of subjects: 4352

Group type: EXPERIMENTAL
Intervention: NT-proBNP and cTnI together
Number of subjects: 4352

Group type: EXPERIMENTAL
Intervention: cTnI
Number of subjects: 4352

Group type: EXPERIMENTAL
Intervention: NT-proBNP added to a model adjusted for TIMI risk score incorporating cTnI
Number of subjects: 4352

Group type: EXPERIMENTAL
Intervention: MPO and hs-CRP
Number of subjects: 4352
Study: 19649552

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 80